Therapix biosciences ltd. (TRPX)
CashFlow / Yearly
Dec'17Dec'16Dec'15
Net loss

-6,244

2,007

2,617

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

5

4

3

Gain from sale of equipment

-1

0

-5

Share-based payment expense

862

327

1,142

Change in liability to the Israeli National Authority for Technological Innovation (''INATI'')

-

0

-49

Company's share in losses of associate

-

0

-51

Finance expenses (incomes), net

-525

-2

67

Gain from sale of investments in investees

-

34

0

Profit loss

1,393

299

1,085

Working capital adjustments:
Increase in accounts receivable

-143

-110

-46

Decrease (increase) in trade payables

349

233

154

Decrease (increase) in other accounts payable

66

111

21

Working capital

272

234

129

Net cash used in operating activities

-4,579

-1,474

-1,403

Cash flows from investing activities:
Increase in restricted cash

-11

0

0

Proceed from sale of equipment

2

0

1

Purchase of equipment

44

4

2

Grant of convertible loan

0

-

-

Proceeds from sale of an investment in previously consolidated subsidiary

-

-1

0

Net cash used in investing activities

-53

-5

-1

Cash flows from financing activities:
Proceeds from exercise of share options and warrants

-

914

1,292

Prepaid public offering costs

18

349

0

Proceeds from issuance of share capital (net of issuance expenses)

13,193

0

1,456

Net cash provided by (used in) financing activities

13,175

565

2,748

Exchange rate differences on cash and cash equivalents in foreign currency

-527

-8

77

Translation differences on cash and cash equivalents

503

25

-5

Increase (decrease) in cash

8,519

-897

1,416